vTv Therapeutics (VTVT) Stock Forecast, Price Target & Predictions
VTVT Stock Forecast
vTv Therapeutics stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
VTVT Analyst Ratings
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Feb 18, 2022 | Cantor Fitzgerald | - | Overweight | Initialise |
vTv Therapeutics Financial Forecast
vTv Therapeutics Revenue Forecast
Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Mar 18 | Mar 17 | Mar 16 | Sep 15 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | $9.00K | - | $4.00K | $3.00M | $9.00K | $987.00K | $6.40M | - | $7.00K | $8.00K | $1.83M | $2.06M | $30.00K | $376.00K | $133.00K |
Avg Forecast | - | - | - | $3.09M | $250.00K | $500.00K | $1.30M | $1.00M | $800.00K | $3.30M | $10.29K | $1.25M | $1.69M | $1.63M | $2.34M | $30.00K | $859.43K | $317.57K |
High Forecast | - | - | - | $3.70M | $250.00K | $500.00K | $1.30M | $1.00M | $800.00K | $3.30M | $12.34K | $1.25M | $1.69M | $1.63M | $2.81M | $36.00K | $1.03M | $381.08K |
Low Forecast | - | - | - | $2.47M | $250.00K | $500.00K | $1.30M | $1.00M | $800.00K | $3.30M | $8.23K | $1.25M | $1.69M | $1.63M | $1.87M | $24.00K | $687.54K | $254.06K |
# Analysts | - | - | - | 12 | 2 | 3 | 4 | 5 | 6 | 6 | 7 | 2 | 2 | 3 | 14 | 9 | 8 | 16 |
Surprise % | - | - | - | 0.00% | - | 0.01% | 2.31% | 0.01% | 1.23% | 1.94% | - | 0.01% | 0.00% | 1.12% | 0.88% | 1.00% | 0.44% | 0.42% |
vTv Therapeutics EBITDA Forecast
Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Mar 18 | Mar 17 | Mar 16 | Sep 15 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | 12 | 2 | 3 | 4 | 5 | 6 | 6 | 7 | 2 | 2 | 3 | 14 | 9 | 8 | 16 |
EBITDA | - | - | - | $-6.08M | $-5.44M | $5.74M | $-959.00K | $-586.00K | $-4.20M | $1.22M | $-3.12M | $-4.10M | $-3.20M | $-2.26M | $-2.06M | $-3.61M | $-3.77M | $-3.66M |
Avg Forecast | - | - | - | $2.45M | $-150.00K | $-300.00K | $-780.00K | $-600.00K | $-2.80M | $-1.98M | $-5.80M | $-753.00K | $-1.01M | $-2.26M | $-2.30M | $-3.61M | $-5.31M | $-5.21M |
High Forecast | - | - | - | $2.94M | $-150.00K | $-300.00K | $-780.00K | $-600.00K | $-2.24M | $-1.98M | $-4.64M | $-753.00K | $-1.01M | $-1.81M | $-1.84M | $-2.89M | $-4.24M | $-4.17M |
Low Forecast | - | - | - | $1.96M | $-150.00K | $-300.00K | $-780.00K | $-600.00K | $-3.36M | $-1.98M | $-6.96M | $-753.00K | $-1.01M | $-2.71M | $-2.76M | $-4.33M | $-6.37M | $-6.25M |
Surprise % | - | - | - | -2.48% | 36.24% | -19.12% | 1.23% | 0.98% | 1.50% | -0.61% | 0.54% | 5.45% | 3.16% | 1.00% | 0.89% | 1.00% | 0.71% | 0.70% |
vTv Therapeutics Net Income Forecast
Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Mar 18 | Mar 17 | Mar 16 | Sep 15 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | 12 | 2 | 3 | 4 | 5 | 6 | 6 | 7 | 2 | 2 | 3 | 14 | 9 | 8 | 16 |
Net Income | - | - | - | $-5.89M | $-4.26M | $8.23M | $-1.09M | $-608.00K | $-4.24M | $1.13M | $-3.37M | $-4.40M | $-3.61M | $-2.88M | $-2.95M | $-4.22M | $-3.85M | $-4.10M |
Avg Forecast | $-20.49M | $-23.05M | $-20.49M | $2.27M | $-11.10M | $-16.22M | $-16.65M | $-17.93M | $-2.83M | $-14.09M | $-4.12M | $-24.33M | $-28.18M | $-2.88M | $-3.30M | $-4.22M | $-5.42M | $-5.84M |
High Forecast | $-20.49M | $-23.05M | $-20.49M | $2.73M | $-11.10M | $-16.22M | $-16.65M | $-17.93M | $-2.26M | $-14.09M | $-3.29M | $-24.33M | $-28.18M | $-2.31M | $-2.64M | $-3.38M | $-4.33M | $-4.67M |
Low Forecast | $-20.49M | $-23.05M | $-20.49M | $1.82M | $-11.10M | $-16.22M | $-16.65M | $-17.93M | $-3.39M | $-14.09M | $-4.94M | $-24.33M | $-28.18M | $-3.46M | $-3.96M | $-5.06M | $-6.50M | $-7.01M |
Surprise % | - | - | - | -2.59% | 0.38% | -0.51% | 0.07% | 0.03% | 1.50% | -0.08% | 0.82% | 0.18% | 0.13% | 1.00% | 0.89% | 1.00% | 0.71% | 0.70% |
vTv Therapeutics SG&A Forecast
Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Mar 18 | Mar 17 | Mar 16 | Sep 15 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | 12 | 2 | 3 | 4 | 5 | 6 | 6 | 7 | 2 | 2 | 3 | 14 | 9 | 8 | 16 |
SG&A | - | - | - | $2.39M | $2.63M | $-6.61M | $2.22M | $2.24M | $2.16M | $2.04M | $1.70M | $1.99M | $1.77M | $2.39M | $2.25M | $2.82M | $2.58M | $2.42M |
Avg Forecast | - | - | - | $8.85M | $717.36K | $1.43M | $3.73M | $2.87M | $2.30M | $9.47M | $29.51K | $3.60M | $4.84M | $4.66M | $6.71M | $86.08K | $2.47M | $911.25K |
High Forecast | - | - | - | $10.62M | $717.36K | $1.43M | $3.73M | $2.87M | $2.30M | $9.47M | $35.41K | $3.60M | $4.84M | $4.66M | $8.05M | $103.30K | $2.96M | $1.09M |
Low Forecast | - | - | - | $7.08M | $717.36K | $1.43M | $3.73M | $2.87M | $2.30M | $9.47M | $23.61K | $3.60M | $4.84M | $4.66M | $5.37M | $68.87K | $1.97M | $728.99K |
Surprise % | - | - | - | 0.27% | 3.67% | -4.61% | 0.60% | 0.78% | 0.94% | 0.21% | 57.43% | 0.55% | 0.37% | 0.51% | 0.34% | 32.81% | 1.05% | 2.65% |
vTv Therapeutics EPS Forecast
Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Mar 18 | Mar 17 | Mar 16 | Sep 15 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | 12 | 2 | 3 | 4 | 5 | 6 | 6 | 7 | 2 | 2 | 3 | 14 | 9 | 8 | 16 |
EPS | - | - | - | $-0.07 | $-0.05 | $0.12 | $-0.02 | $-0.01 | $-0.08 | $0.02 | $-0.07 | $-0.13 | $-0.13 | $-0.10 | $-0.30 | $-0.44 | $-0.42 | $-0.49 |
Avg Forecast | $-3.20 | $-3.60 | $-3.20 | $-2.53 | $-1.73 | $-2.53 | $-2.60 | $-2.80 | $-2.40 | $-2.20 | $-3.80 | $-3.80 | $-4.40 | $-4.20 | $-0.38 | $-0.44 | $-1.35 | $-1.67 |
High Forecast | $-3.20 | $-3.60 | $-3.20 | $-2.53 | $-1.73 | $-2.53 | $-2.60 | $-2.80 | $-2.40 | $-2.20 | $-3.80 | $-3.80 | $-4.40 | $-4.20 | $-0.30 | $-0.35 | $-1.08 | $-1.33 |
Low Forecast | $-3.20 | $-3.60 | $-3.20 | $-2.53 | $-1.73 | $-2.53 | $-2.60 | $-2.80 | $-2.40 | $-2.20 | $-3.80 | $-3.80 | $-4.40 | $-4.20 | $-0.46 | $-0.53 | $-1.62 | $-2.00 |
Surprise % | - | - | - | 0.03% | 0.03% | -0.05% | 0.01% | 0.00% | 0.03% | -0.01% | 0.02% | 0.03% | 0.03% | 0.02% | 0.79% | 1.00% | 0.31% | 0.29% |
vTv Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
ELEV | Elevation Oncology | $0.52 | $9.00 | 1630.77% | Buy |
KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
GOVX | GeoVax Labs | $1.79 | $8.00 | 346.93% | Buy |
IMMX | Immix Biopharma | $1.58 | $7.00 | 343.04% | Buy |
ERAS | Erasca | $2.87 | $7.00 | 143.90% | Buy |
PYXS | Pyxis Oncology | $3.80 | $9.00 | 136.84% | Buy |
CCCC | C4 Therapeutics | $6.45 | $13.50 | 109.30% | Buy |
EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
ZURA | Zura Bio | $4.37 | $5.00 | 14.42% | Buy |
EFTR | eFFECTOR Therapeutics | - | $5.50 | - | Buy |
VTVT | vTv Therapeutics | $14.00 | $5.00 | -64.29% | Buy |
VTVT Forecast FAQ
Is vTv Therapeutics a good buy?
Yes, according to 1 Wall Street analysts, vTv Therapeutics (VTVT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of VTVT's total ratings.
What are vTv Therapeutics's analysts' financial forecasts?
VTVT's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-64.034M (high $-64.034M, low $-64.034M), average SG&A $0 (high $0, low $0), and average EPS is $-10 (high $-10, low $-10).
Did the VTVT's actual financial results beat the analysts' financial forecasts?
Based on vTv Therapeutics's last annual report (Dec 2022), the company's revenue was $2.02M, which missed the average analysts forecast of $3.34M by -39.50%. Apple's EBITDA was $-24.858M, missing the average prediction of $2.3M by -1178.99%. The company's net income was $-25.073M, beating the average estimation of $-8.825M by 184.11%. Apple's SG&A was $12.2M, beating the average forecast of $9.57M by 27.48%. Lastly, the company's EPS was $-0.53, missing the average prediction of $-4.267 by -87.58%. In terms of the last quarterly report (Dec 2022), vTv Therapeutics's revenue was $9K, missing the average analysts' forecast of $3.09M by -99.71%. The company's EBITDA was $-6.084M, missing the average prediction of $2.45M by -347.94%. vTv Therapeutics's net income was $-5.89M, missing the average estimation of $2.27M by -359.02%. The company's SG&A was $2.39M, missing the average forecast of $8.85M by -73.03%. Lastly, the company's EPS was $-0.0723, missing the average prediction of $-2.533 by -97.15%